The Human Variable 

CRISPR²™ (CRISPR Readiness Index, Stabilization, Personalized Recovery) introduces a state-dependent framework for gene editing in complex chronic disease. Unlike conventional models that assume biological stability, CRISPR² integrates patient readiness, environmental exposure, temporal symptom dynamics, and recovery conditions to guide when and how intervention occurs. This approach expands therapeutic reach across severity levels, improves interpretation of outcomes in vari

Stage Zero™ defines the preclinical phase where immune and autonomic instability is already active but not yet captured by traditional diagnostics. By identifying structured symptom patterns, timing-based responses, and multi-system disruption, this framework enables earlier recognition of disease activity across conditions such as Long COVID, ME/CFS, POTS, and autoimmune disorders. Rather than waiting for diagnostic thresholds, Stage Zero™ introduces a trajectory-based model

Why rheumatoid arthritis is often misdiagnosed or delayed. Learn early RA symptoms, diagnostic gaps, and how CDF-RA™ improves early detection.

A field guide for designing Lyme disease clinical trials that work. Learn how to improve outcomes using adaptive design, co-infection stratification, digital biomarkers, and CYNAERA’s stabilization-first framework.

The Target Readiness Index™ (TRI) introduces a state-dependent framework for CRISPR target prioritization across ME/CFS, Long COVID, Lyme disease, and autoimmune conditions including lupus, type 1 diabetes, Hashimoto’s, and Sjögren’s.

SymCas™ is a flare prediction model for POTS, Lyme disease, ME/CFS, Long COVID and relapsing chronic conditions. It identifies symptom patterns over time to detect early instability and support proactive care.